Pfizer’s Revatio flops in Phase 3 trial

pharmafile | July 1, 2019 | News story | Sales and Marketing  

American multinational Pfizer has said that Revatio (Sildenafil Citrate) in combination with nitric oxide, has failed to meet its primary endpoint in a Phase 3 trial.

Pfizer’s Revatio combination therapy has flopped in a late-stage trial testing the drug’s effectiveness in treating new-born babies with persistent pulmonary hypertension.

The combination of inhaled nitric oxide and intravenously administered Revatio did not result in a reduction in the rate of treatment failure of inhaled nitric oxide, or in the amount of time new-born babies spent being treated with inhaled nitric oxide, compared to nitric oxide alone.

The second part of the trial is still ongoing as trial administrators will follow-up participants at 12 and 24 months after the end of the initial treatment to evaluate the developmental progress.

Revatio bares similarities to Pfizer’s erectile dysfunction drug Viagra (sildenafil) which was first developed to treat adults with high blood pressure in the lungs.

Louis Goss

Related Content

No items found

Latest content